Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Metastatic Breast Cancer
About this trial
This is an interventional treatment trial for Metastatic Breast Cancer
Eligibility Criteria
Inclusion Criteria: HER-2/neu overexpression assessed by FISH test or with immunohistochemical methods: Dako(the result must be 3+ with dakotest); if the immunohistochemical test results 2+ it is needed a positive FISH test Female < 70yrs Histologically or cytologically proven breast cancer. Metastatic or locally advanced breast cancer (clinical stage: III-IV) Adequate hematological, hepatic, renal and cardiac function, the latter confirmed by echocardiography with FEVS ≥50% Prior adjuvant chemotherapy if doxorubicin total dose ≤300 mg/m2, epirubicin total dose ≤450 mg/m2 Exclusion Criteria: History of cardiopathy Severe hepatic and renal diseases Brain metastases as the only parameter of disease Contraindication to the use of corticosteroids as premedication Acute infectious diseases Insulin-dependent diabetes History of other cancers except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix Concurrent treatment with any other cancer therapy
Sites / Locations
- Ospedale PietrantoniRecruiting